A Focus on Riociguat in the Treatment of Pulmonary Arterial Hypertension

Basic and Clinical Pharmacology and Toxicology - United States
doi 10.1111/bcpt.13272
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2018English

Riociguat Is a Novel Medication for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Medical Council
2016English

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center

Cardiology and Therapy
2015English

Treatment of Pediatric Pulmonary Arterial Hypertension: A Focus on the NO‐sGC‐cGMP Pathway

Pediatric Pulmonology
Child HealthPulmonaryPediatricsPerinatologyRespiratory Medicine
2019English

Role of Riociguat in Treatment of Exercise-Induced Pulmonary Hypertension

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Initial Riociguat Monotherapy and Transition From Sildenafil to Riociguat in Patients With Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling

Lung
PulmonaryRespiratory Medicine
2018English

EXPRESS: First-In-Child Use of the Oral Soluble Guanylate Cyclase Stimulator Riociguat in Pulmonary Arterial Hypertension

Pulmonary Circulation
PulmonaryRespiratory Medicine
2017English

Treatment of Pulmonary Arterial Hypertension in Pregnancy

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2007English

Surgical Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy